Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Breast Cancer treatment details. Biologic therapy. Chemotherapy. Centre GF Leclerc, Dijon, France

Survival: ?
Toxicity Grade: 4
Treatments: Biologic therapy
Drugs: Herceptin
Country: France
City/State/Province: Dijon
Hospital: Centre GF Leclerc
Journal: Link
Date: 12/2005

Patients: This Phase II study involved 33 women with HER2-over-expressing stage II or III breast cancer. The patients wished to conserve their affected breasts. The median age was 45.

Treatment: The treatment consisted of a chemotherapy agent - docetaxel and a biological therapy (monoclonal antibody)- trastuzumab.

Toxicity: Grade 1-4 toxicities included neutropenia, elevated liver enzymes, leukopenia, and alopecia.

Results: The median overall survival was not reported, but 22 patients had a complete response and seven a partial response to treatment. Twenty-three patients conserved their breasts, and the mean tumor size decreased significantly.

Support: Roche Laboratories and Sanofi-Aventis Laboratories financially supported this study, and several authors are employees of those companies. Roche manufactures and/or markets trastuzumab. Sanofi-Aventis manufactures and/or markets docetaxel.

Correspondence: Dr B. Coudert

E-mail to a Friend Email Physician More Information